CD52-directed Cytolytic Antibody

Name

CD52-directed Cytolytic Antibody

Accession Number

DBCAT003274

Description

Not Available

Drugs

Drug	Drug Description
Alemtuzumab	A monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis.

Drugs & Drug Targets

Drug	Target	Type
Alemtuzumab	CAMPATH-1 antigen	target
Alemtuzumab	Low affinity immunoglobulin gamma Fc region receptor III-B	target
Alemtuzumab	Low affinity immunoglobulin gamma Fc region receptor III-A	target
Alemtuzumab	High affinity immunoglobulin gamma Fc receptor I	target
Alemtuzumab	Low affinity immunoglobulin gamma Fc region receptor II-a	target
Alemtuzumab	Low affinity immunoglobulin gamma Fc region receptor II-b	target
Alemtuzumab	Low affinity immunoglobulin gamma Fc region receptor II-c	target